sponsored
PatientsVille.com Logo

PatientsVille

Hydrodiuril Medical Research Studies

Up-to-date List of Hydrodiuril Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hydrodiuril Medical Research Studies

Rank Status Study
1 Unknown  Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
Conditions: Hypertension;   Renal Insufficiency
Interventions: Drug: Indapamide;   Drug: Hydrochlorothiazide
Outcome Measures: renal function;   endothelial function;   blood pressure variability
2 Unknown  Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: Aliskiren;   Drug: Hydrochlorothiazide
Outcome Measure: Renal oxygenation measured by renal BOLD-MRI after chronic treatment with aliskiren or hydrochlorothiazide
3 Unknown  A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients
Condition: Congestive Heart Failure
Intervention: Drug: metolazone or hydrochlorothiazide
Outcome Measures: The primary endpoint will be change in urinary output.;   Secondary endpoints will be changes in weight, neurohormones (angiotensin II, catecholamines, brain natriuretic peptide, aldosterone), and electrocardiographic parameters of ventricular instability.
4 Not yet recruiting Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects
Condition: Healthy Subjects
Interventions: Drug: Atorvastatin;   Drug: Hydrochlorothiazide + Losartan;   Drug: Hydrochlorothiazide + Losartan + Atorvastatin
Outcome Measures: The primary pharmacokinetic parameters for the exercise of comparability will be unchanged dosages of analytes (AT, LS and HCTZ), assessed by AUC, Tmax, Cmax and T1 / 2.;   Pharmacokinetic parameters are side dosages of active metabolites O-HAT and E-3174, measured by AUC, Tmax, Cmax and T1 / 2.
5 Recruiting Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function
Condition: Hypertension
Interventions: Drug: Chlorthalidone 12.5 mg;   Drug: Hydrochlorothiazide 25 mg;   Drug: Placebo
Outcome Measure: Flow mediated vasodilatation
6 Recruiting Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
Condition: Essential Hypertension
Interventions: Drug: CS8635 20/5/12.5mg and placebo;   Drug: Olmetec® Plus 20/12.5mg and placebo
Outcome Measures: The changes of seated diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   The changes of mean seated systolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   The changes of mean seated systolic and diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   Percentage of subjects achieving blood pressure goal of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   Percentage of subjects achieving blood pressure goal of the Triple Combinations OM/AML/HCTZ 40/5/12.5mg vs.OM/AML/HCTZ 20/5/12.5mg;   The changes of mean seated systolic and diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 40/5/12.5mg vs.OM/AML/HCTZ 20/5/12.5mg
7 Recruiting Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function
Conditions: Chronic Kidney Insufficiency;   Hemodialysis Treatment;   Diuresis Preserved
Intervention: Drug: Hydrochlorothiazide and furosemide
Outcome Measures: To asses the effect of combined hydrochlorothiazide-furosemide therapy on weight gain between haemodialysis sessions in patients with RRF;   To asses the effect of combined hydrochlorothiazide-furosemide therapy on dialytic, clinical and analytical variables and use of the antihypertensive treatment
8 Recruiting Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use
Condition: Healthy
Interventions: Drug: Amlodipine 5mg capsule;   Drug: T80/H12.5 mg FDC tablet;   Drug: T80/A5/H12.5 mg FDC tablet
Outcome Measures: Maximum measured concentration (Cmax) of the analyte in plasma;   Area under the concentration-time curve (AUC 0-tz) of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration;   Area under the concentration-time curve (AUC 0-infinity) of the analyte in plasma over the time interval from 0 to extrapolated infinity
9 Recruiting Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome
Condition: Hypertension
Interventions: Drug: amlodipine/valsartan;   Drug: hydrochlorothiazide/telmisartan
Outcome Measure: To assess the glucose change
10 Unknown  Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
Condition: Essential Hypertension
Intervention: Drug: telmisartan plus hydrochlorothiazide
Outcome Measures: Changes in office blood pressure;   1) Home blood pressure in early morning and before going to bed 2) Changes in uric acid, total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, fasting plasma glucose (only in diabetic patients), hemoglobin A1c (only in diabetic patients
11 Recruiting Chlorthalidone and HCTZ Impacts on Platelet Activation
Condition: Hypertension
Interventions: Drug: Chlorthalidone 12.5 mg;   Drug: Hydrochlorothiazide 25 mg;   Drug: Aspirin 81 mg
Outcome Measures: Change in mean fluorescence intensity of PAC-1;   Change in CD62P expression;   Change in platelet aggregation
12 Recruiting Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
Conditions: Proteinuria;   Hypertension;   Type II Diabetes
Interventions: Drug: Amiloride;   Drug: HCTZ
Outcome Measures: Blood Pressure;   Hypertension
13 Recruiting Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
Conditions: Hypertension, Resistant to Conventional Therapy;   Essential Hypertension
Interventions: Drug: Losartan and hydrochlorothiazide;   Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks
Outcome Measures: Change in mean home systolic BP for the group treated initially with monotherapy compared to the group treated initially with combination therapy.;   A comparison the proportion of patients who drop out of the trial at any stage after randomisation or who require further antihypertensive treatment
14 Not yet recruiting EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network
Condition: Hypertension
Interventions: Drug: Chlorthalidone;   Drug: Hydrochlorothiazide
Outcome Measures: Mean systolic 24 Hour Ambulatory Blood Pressure;   Subjective Medication Side Effects
15 Recruiting Vascular Dysfunction in Human Obesity Hypertension
Conditions: Obesity;   Prehypertension;   Hypertension
Interventions: Drug: Clonidine;   Drug: Hydrochlorothiazide;   Drug: Placebo
Outcome Measures: Forearm endothelium-dependent dilation (EDD);   Forearm endothelium-independent dilation (EID);   Muscle sympathetic nerve activity;   Endothelial cell oxidative stress and RAS proteins
16 Not yet recruiting Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use
Condition: Healthy
Interventions: Drug: T80/A5 mg FDC tablet;   Drug: H12.5 mg tablet;   Drug: T80/A5/H12.5 ng FDC tablet;   Drug: H12.5 mf tablet;   Drug: T80/A5/H12.5 mg FDC tablet
Outcome Measures: Maximum measured concentration (Cmax) of the analyte in plasma;   Area under the concentration-time curve (AUC 0-tz) of the analyte in plasma over the time interval from 0 to the last quantifiable plasma concentration;   Area under the concentration-time curve (AUC 0-infinity) of the analyte in plasma over the time interval from 0 extrapolated to infinity
17 Recruiting Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Condition: Metabolic Syndrome
Interventions: Drug: Ramipril;   Drug: HCTZ-hydrochlorothiazide;   Drug: Ramipril+HCTZ
Outcome Measure: Changes in Insulin Sensitivity
18 Recruiting Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Condition: Acute Autoimmune Optic Neuritis
Interventions: Drug: Amiloride hydrochlorothiazide;   Drug: Sugar pill
Outcome Measure: Change in thickness of retinal nerve fiber layer (RNFL)
19 Unknown  Regression of Fatty Heart by Valsartan Therapy
Conditions: Metabolic Syndrome;   Lipotoxicity
Interventions: Drug: Valsartan;   Drug: Hydrochlorothiazide
Outcome Measures: Myocardial triglyceride levels;   Hepatic triglyceride levels, insulin sensitivity, abdominal fat mass
20 Recruiting ACE Inhibitors Combined With Exercise for Seniors - Pilot Study
Conditions: Hypertension;   Aging
Interventions: Behavioral: Exercise;   Drug: ACE inhibitor + exercise;   Drug: Thiazide diuretic + exercise;   Drug: Angiotensin receptor blocker + exercise
Outcome Measures: Change in Walking Speed;   Change in body composition;   Changes in circulating indices of cardiovascular risk;   Change in Exercise Capacity

These studies may lead to new treatments and are adding insight into Hydrodiuril etiology and treatment.

A major focus of Hydrodiuril research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hydrodiuril